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The best way of managing an extra-articular fracture of the distal tibia remains disputed. Although plates and intramedullary (IM) nails are two viable methods of fixing these fractures, each possesses distinct disadvantages. With intramedullary nailing, the bolts or screws that are inserted across the nail may break, malalignment of the bone may occur, and there is an increased risk of anterior knee pain. 1 While tibial plating using a 'locking' plate can achieve accurate reduction, the need for greater softtissue dissection increases the risk of infection, wound breakdown, and damage to the surrounding structures. 1, 2 Evidence from previous meta-analyses and systematic reviews, which compared the two techniques, have been inconclusive. Mao et al 3 reviewed 1863 extra-articular fractures of the distal tibia and reported that rates of deep infection, delayed union, and removal of instrumentation were similar for patients undergoing the two types of fixation, but that nail fixation was associated with significantly more malunions. By contrast, Zelle et al 4 found that malunion rates were similar in the two treatment groups. However, the studies included in the meta-analyses had heterogeneous study designs and the randomized controlled trials lacked methodological rigour. 3 The prolonged recovery and rehabilitation from a distal tibia fracture, along with the complications associated with treatment choice, have important economic consequences. These injuries not only generate direct treatment costs but also indirect costs which include loss of income because of absence from work. Given rapidly escalating healthcare costs, and the need to allocate finite health care resources more efficiently, the costs associated with nail and locking plate fixation should be considered as well as the clinical benefits. Data that compare the clinical outcome and cost-effectiveness of intramedullary nail and locking plate management of distal tibial fractures are currently limited. Available data are based on assessments of intramedullary nails alone, 5 are based on different plates for fixation alone, 6 or compare nail fixation with interventions other than locking plates.
We present a prospectively conducted health economic evaluation derived from a multicentre randomized controlled trial of intramedullary nail fixation and locking plate fixation for the treatment of adult patients with a displaced fracture of the distal tibia.
Patients and Methods
Trial background. Data from the Fixation of Distal Tibia Fractures (UK FixDT) trial formed the basis of the economic evaluation. 7 Briefly, patients were eligible for the trial if: they had a fracture that involved the distal tibial metaphysis; they were aged 16 years or over; and the treating surgeon believed that they would benefit from internal fixation of the fracture. Participants were recruited from 28 United Kingdom Trauma Hospitals between April 2013 and February 2016 and were followed up for one year. They were randomly allocated to either intramedullary nail fixation or locking-plate fixation. All surgery was performed according to the preferred technique of the operating surgeon. A sample size of 320 was required to detect a difference of eight points in the primary clinical outcome, the disability rating index (DRI), with 90% power at the 5% level. Full details of the trial protocol are available in open access. Study perspective and time horizon. The primary analysis was undertaken from the perspective of the United Kingdom National Health Service (NHS) and Personal Social Services (PSS) as recommended by the National Institute of Health and Care Excellence (NICE). 8 The time horizon for the economic evaluation followed the 12-month follow-up period of the trial, and therefore no discounting of costs and benefits was required. Under normal circumstances, an uncomplicated fracture of the distal tibia would be expected to be clinically united at six months and the patient returned to normal activities. 2, 9 The 12-month follow-up period is thus well suited to capture both clinically important differences between the two procedures and any nonunions resulting in revision fixation and rehospitalization. Measurement and valuation of resource use. Estimation of the costs associated with the interventions included the cost of the initial surgery and the broader health and PSS resource inputs, plus, for the purposes of a sensitivity analysis, personal costs and broader societal resource inputs. All costs were expressed in pounds sterling and valued in 2014-15 prices. Where appropriate, costs were inflated or deflated to 2014-15 prices using the NHS Hospital and Community Health Services Pay and Prices Index.
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Cost of distal tibia fixation. The initial surgical costs (intervention costs) were based on the initial hospital stay and associated operative costs as reported in Table I . Unit costs were estimated using NHS reference costs and the Healthcare Resource Groups (HRG) tariff for 'major knee procedures for trauma'. 11 Based on this tariff, operative fixation of a distal tibial fracture costs the NHS £5315.47 if a patient stays in hospital for five days. Costs of the initial surgery were derived for each patient using the mean length of stay reported in the patient records. An excess of £327.00 per day was used to adjust the surgical costs of patients who stayed in hospital for longer than five days. We assumed that treatment costs were disproportionately weighted towards the first three days of each initial hospital admission. Thus, the cost to the NHS of a patient who stayed in hospital for three days was calculated as £5315.47 -(2 × £327), i.e. the five-day tariff minus the bed-day cost of £327 per each day not spent in hospital. The numbers of the NHS supply chain catalogue, 17 and the British National Formulary (BNF).
18 Table II summarizes the unit cost values and data sources for broader resource inputs. Measurement and valuation of health outcomes. In line with the NICE reference case, the primary health outcome for the economic evaluation was the quality-adjusted-life-year (QALY), 8 which combines the impacts on both health-related quality of life (HRQoL) and length of life. 19 HRQoL was assessed using the EQ-5D-3L questionnaire (referred to from henceforth as EQ-5D for brevity) 20 at baseline and at three, six, and 12 months post-randomization. The EQ-5D comprises five dimensions: 'mobility', 'self-care', 'usual activities', 'pain/ discomfort', and 'anxiety/depression'. Responses in each dimension have three levels: no problems; moderate problems; and extreme problems. EQ-5D health states can be converted into a single summary index by applying a utility algorithm, which attaches values to each permutation of responses to the EQ-5D descriptive system. We applied utility values for EQ-5D health states elicited from a general population sample in the United Kingdom using the time-trade-off method. 21 Utility values generated through this method range from -0.59 to 1.0, where 0 represents death, 1.0 represents full health, and values below 0 indicate health states worse than death. QALY values for each patient were estimated by calculating the area under the baseline-adjusted utility curve, and were calculated using linear interpolation between baseline and follow-up utility scores. Missing data. For the baseline analysis, multiple imputation under chained equations (MICE) 22 was used to model missing data for those cases where resource use or HRQoL data were unavailable, based on the tested assumption that data were missing at random. Regression models were used to impute unobserved costs and QALYs at each timepoint, and by treatment allocation, using age and gender as explanatory variables. Costs and EQ-5D utility scores at each timepoint contributed as both explanatory and imputed variables. The imputation was run 50 times following the rule of thumb that the number of imputations should be similar to the percentage of incomplete cases. 22 A total of 50 data sets were generated using predictive mean matching. Each imputed data set produced was independently analyzed with bivariate regressions using a seemingly unrelated regression model to estimate the costs and QALYs in each treatment group over the 12-month trial horizon. Estimates from each imputed dataset were combined using Rubin's rule to generate overall mean costs and QALY estimates and their standard errors.
23
Analyses of resource use, costs, and outcome data. Resource use items were summarized by treatment group and follow-up period and differences between groups were analyzed using Student's t-tests for continuous variables and chi-squared tests for categorical variables. Means and standard errors (SE) for values of each cost category were estimated by treatment allocation and follow-up period and statistical differences in mean costs by treatment allocation were assessed using Student's t-tests. Mean total costs by treatment allocation and follow-up period were also estimated. Statistically significant differences in the mean total costs were assessed using non-parametric bootstrapping, based on 10 000 replications.
For each of the five dimensions of the EQ-5D, we calculated the proportion of patients reporting suboptimal function (moderate or extreme problems) and assessed differences between groups using chi-squared tests. Cost-effectiveness analysis. Cost-effectiveness results were expressed in terms of an incremental cost-effectiveness ratio (ICER) and calculated by dividing the difference between treatments in mean total costs by the mean difference in total QALYs. The ICER represents the additional cost required to gain a QALY and, in our case, indicates whether investing additional resources on a particular type of fixation is costeffective. As a general rule, NICE considers interventions costing the NHS less than £20 000 per QALY gained to be costeffective. 24 To determine the level of sampling uncertainty around the ICER, we conducted non-parametric bootstrapping, generating 50 000 estimates of incremental costs and benefits. 25 The bootstrap replicates from the non-parametric bootstrapping were used to populate cost-effectiveness scatterplots. We calculated the net monetary benefit (NMB) of using nail fixation rather than locking plate fixation across three costeffectiveness thresholds: £15 000 per QALY, £20 000 per QALY, and £30 000 per QALY. 26 A positive incremental NMB indicates that the intervention is cost-effective compared with the alternative at the given cost-effectiveness threshold. Furthermore, cost-effectiveness acceptability curves (CEACs) were generated based on the proportion of bootstrap replicates with positive incremental net benefits. The CEACs indicate the probability that nail fixation is cost-effective relative to locking plate fixation across a range of cost-effectiveness thresholds. Sensitivity and subgroup analyses. Several sensitivity analyses were undertaken to assess the impact of parameters with a degree of uncertainty on cost-effectiveness outcomes. These included: restricting the analyses to complete cases (i.e. those with complete cost and outcome data over the 12-month follow-up period); adopting a wider societal perspective that included private costs incurred by trial participants and their families, productivity losses and loss of earnings due to work absences; estimating the cost-effectiveness under a per-treatment analysis; and additionally adjusting the baseline analysis for preinjury HRQoL, which was assessed using the EQ-5D at baseline.
Subgroup analyses were also conducted for the main costeffectiveness results to explore heterogeneity in the trial population. These were conducted by age group (< 50 years and ≥ 50 years) and gender (male, female). Longer-term economic modelling. The study protocol allowed for decision-analytical modelling to estimate the costeffectiveness of intramedullary nail fixation over a longer-term Beyond the 12-month follow-up period assessed in this study, rehospitalization and reoperation are possible due to excess complications. 3 We conducted a preliminary analysis of the extended follow-up data for this trial to determine whether differences in HRQoL outcomes, metalwork removal and in rates of complications persisted at 24 months. Furthermore, we systematically searched external studies that compared plate and nail fixation for evidence on clinically important differences beyond 12-months post-surgery. Although we did not find good-quality external evidence, analysis of the composite of available data indicates that, beyond 12 months, rates of deep infection and wound healing are similar. 2, 3, 27 According to a recent analysis of 358 patients in Belgium, total length of stay in hospital (due to initial surgery and reoperations) and rate of deep infections are the major costdrivers for fractures of the tibial shaft. 28 The combined evidence thus indicated that clinical and economic differences between nail and plate fixation are probably concentrated in the first year following surgery. This informed our decision not to undertake longer-term economic modelling.
Results
Between April 2013 and February 2016, 321 patients were recruited and randomized (nail fixation, n = 161; locking plate, n = 160). Three patients did not complete the baseline questionnaires. A total of 276 patients completed the threemonth questionnaire, while 284 and 258 patients returned questionnaires at the six-and 12-month follow-up timepoints, respectively. Overall, the follow-up rate was greater than 80% at all timepoints. The trial results based on the primary clinical outcome measure, as well as details on time to union, postoperative complications at the six-week assessment, and the number and type of further surgical interventions associated with the fracture in each group within 12 months of initial surgery are presented elsewhere.
7 Table III shows the volume of missing health economic data by treatment allocation and follow-up timepoint. The missing data pattern was nonmonotonic since several individuals with missing data at one follow-up timepoint completed subsequent questionnaires. Resource use. Resource use was generally higher for participants allocated to the locking plate group than for those allocated to nail group, but this was not always statistically significant (supplementary tables i to iv). The exceptions, which showed statistically significant differences, were the mean total inpatient stay between three and six months (0 days (nail) versus 0.11 days (locking plate)), and mean total outpatient care contacts between three and six months (3.64 contacts versus 4.78 contacts). The differences in outpatient care appear to be driven by increased physiotherapy contacts in the locking plate group (1.84 visits versus 2.53 visits). Costs. The mean intervention costs from admission until discharge were £5460 for nail fixation compared with £5600 for locking plate fixation; a mean difference of £140 (95% confidence interval (CI) -684.24 to 262.61; p = 0.19) (Table IV) The mean length of the initial hospital stay was 3.87 days (SE 0.34) for nail fixation and 3.85 days (SE 0.33) for locking plate fixation. The mean total NHS and PSS cost throughout the first six months post-randomization was £5876 for nail fixation and £6814 for locking plate fixation; the mean cost difference of £939 was statistically significant at the 5% significance level (p = 0.04). The mean total NHS and PSS cost for the entire 12-month follow-up period was £6107 for nail fixation and £7102 for locking plate fixation; the mean cost difference of £995 was statistically significant at the 10% significance level (p = 0.05). Productivity losses to employers through sickness absences appeared higher in the locking plate arm, and the difference for the entire follow-up period was statistically significant at the 10% level. Overall societal costs, for the entire follow-up period, were a mean of £3396 higher in the locking plate group; this cost difference was statistically significant at the 5% level (p = 0.01) ( Table V) . Health-related quality of life outcomes. Supplementary tables v to viii summarize the number and proportion of reported problems for each level for each dimension of the EQ-5D. The proportion of trial participants reporting suboptimal function is also indicated for each dimension and the difference between the two treatment arms shown using p-values. With the exception of mobility at three months (81% nail versus 89% locking plate), which was statistically significant at the 10% significance level, there was no significant differences in the proportion of individuals reporting suboptimal function within dimensions between the two arms at each timepoint. The EQ-5D utility scores preinjury and postinjury (baseline), as well as at three, six, and 12 months post-randomization, are shown in Table VI and Figure 1 . Both groups showed improvement in HRQoL from baseline to the last follow-up point. The most notable difference was observed at six months post-randomization with a higher utility value observed for the nail fixation group (p = 0.03).
The mean total QALYs (imputed) over the 12 months for IM nail and locking plate fixation were 0.55 and 0.54 respectively, but the difference was not statistically significant (0.01 QALYs, 95% CI -0.03 to 0.06; p = 0.56).
Cost-effectiveness analysis. The baseline economic evaluation, using imputed attributable costs and QALYs and covariate adjustment, indicated that intramedullary nail fixation was associated with significantly lower mean NHS and PSS costs (-£970, 95% CI -1685 to -256) and a non-statistically significant increase in QALYs (0.01 QALYs, 95% CI -0.03 to 0.06) over the entire 12-month follow-up period (Table VII) . Uncertainty surrounding the ICER estimates is represented graphically in the cost-effectiveness plane (Fig. 2) , which shows that most simulated ICER values fall in the south-east quadrant, indicating that nail fixation is, on average, less costly and more effective (i.e. it produced more QALYs). The probability of cost-effectiveness given the uncertainty surrounding the mean ICER value is visually displayed in the CEAC. The probability that nail fixation is costeffective ranged between 94% and 98% across cost-effectiveness thresholds of £15 000 to £30 000 per QALY (Table VII; Fig. 3 ). The net monetary benefit for IM nail, for the base case, was positive (incremental NMB values > £1200). Sensitivity and subgroup analyses. Most of the sensitivity analyses undertaken (complete case, societal perspective, and imputed attributable costs and QALYs additionally controlled for preinjury utility) supported the base case finding (Table  VII) . However, the per-treatment analysis showed a slightly different pattern for QALY outcomes. The results for that analysis indicated that participants in the nail fixation arm, on average, experienced slightly worse QALY outcomes (-0.01 QALYs (95% CI -0.06 to 0.04)). However, the result was not statistically significant. Moreover, the cost difference remained in the same direction (-875, 95% CI -1725 to -26)) as that for the base case analysis. The results of the subgroup analyses indicate that in the sample of patients below the age of 50, nail fixation was the dominant intervention; it lowered costs and moderately increased QALYs (Table VII) . In patients over the age of 50 years, nail fixation was associated with lower costs (-£821) and lower benefits (-0.022 QALYs), on average, than locking plate fixation. However, the 95% confidence intervals for both the incremental cost (95% CI -2760 to 1110) and QALY (95% CI -0.09 to 0.05) estimates suggest considerable uncertainty surrounding the effects of intramedullary nail fixation for this older group of patients.
Discussion
This study shows that nail fixation 'dominates' locking plate fixation in health economic terms. This conclusion is driven by the finding that there was a modest QALY gain in the nail group over the 12-month time horizon of the trial and costs were significantly lower in the nail group. In addition, there was a high probability that nail fixation is cost-effective across cost-effectiveness thresholds recommended by decisionmakers, a finding that remained robust to most sensitivity and subgroup analyses. The main exception to this pattern of results was the subgroup of patients over the age of 50 years in whom nail fixation was associated with a reduction in costs, but also marginally lower QALYs, although there was substantial uncertainty around the estimates. A retrospective review of 42 patients (> 50 years old) found that older patients who sustained a fracture of the tibial shaft treated by intramedullary nailing took longer to heal, and required more procedures to achieve union. 29 This external evidence suggests that other factors may need to be taken into account when deciding the optimal treatment approach for distal tibia fractures in the elderly.
To our knowledge, this is the first trial-based economic evaluation to compare the cost-effectiveness of these two surgical procedures for the treatment of fractures of the distal tibia. Previous studies have compared two types of intramedullary nails (reamed versus unreamed) in treating open and closed tibia fractures; however, they did not compare intramedullary nails to other interventions. 5 Busse et al 30 reported costs associated with treatment of low-energy tibial fractures with casting, casting with therapeutic ultrasound, and intramedullary nailing (with and without reaming) by use of a decision tree model. 30 The results of that analysis indicated that intramedullary nailing was the treatment of choice for closed and open grade I tibial shaft fractures: however, the impact on HRQoL was not assessed. Kao et al 6 conducted a cost-effectiveness analysis comparing conventional buttress or dynamic compression plates and locking plates for treating displaced distal tibial fractures, but did not conduct a comparative assessment with intramedullary nails. The same interventions have been compared in different clinical contexts, for example, for the treatment of midshaft clavicle fractures, 31, 32 but the cost-effectiveness evidence in those contexts remains limited. 33 The strengths of the current economic evaluation include data collected from a prospective randomized trial with frequent assessments over a 12-month follow-up period and Overall trend in EQ-5D utility score means and 95% confidence intervals (CI) by treatment arm. minimal loss to follow-up. This enabled a trial-based economic evaluation that was rigorous, with effectiveness and cost measures (including indirect patient-reported costs) collected prospectively, and the direct measurement of utility scores from our study participants to calculate QALYs. 34 Furthermore, the economic evaluation was conducted according to nationally agreed design and reporting guidelines. 35 Limitations of this trial-based economic analysis include the fact that long-term cost-effectiveness beyond the 12-month follow-up period was not assessed. However, preliminary analysis of the HRQoL outcomes of the trial participants using extended follow-up data for this trial indicates that EQ-5D utility scores for the nail fixation and locking plate groups remain similar at 24 months post-randomization (extended *Dominance indicates mean costs were less and the mean benefit was greater for intramedullary nail versus locking plate fixation †P 1 , P 2 , P 3 : probability cost-effective if willing to pay £15 000/QALY, £20 000/QALY, or £30 000/QALY, respectively ‡NMB 1 , NMB 2 , NMB 3 : net monetary benefit if willing to pay £15 000/QALY, £20 000/QALY, or £30 000/QALY, respectively CI, confidence interval; ICER, incremental cost-effectiveness ratio; SW, south-west Graph showing the cost-effectiveness plane generated from bootstrapped mean cost and quality-adjusted life-years (QALYs) differences over 12 months for base case (NHS and personal social service perspective, imputed, intention-to-treat analysis).
Cost-effectiveness threshold Probability of cost-effectiveness £10 000 £20 000 £30 000 £40 000 £50 000 £0 follow-up data will be reported in due course). In addition, by 12 months, the rates of metalwork removal, revision fixations, and other secondary operative procedures were similar between the locking plate and nail fixation groups. 7 The indication, therefore, is that the benefits of nail fixation are very likely to be concentrated in the first year of treatment. Furthermore, our systematic search for external studies that compared plate and nail fixation did not find any good-quality evidence on differences in functional outcomes and HRQoL beyond 12 months post-surgery. The available studies were either based on short follow-up periods, 36 small sample sizes, 2 non-randomized studies that relied on retrospective reviews or case series which tend to suffer from selection biases, 2, 37 or a combination of these factors. A second potential limitation is that we used NHS tariffs to estimate total cost of the surgical treatment, which some have argued do not fully capture the cost of orthopaedic procedures and may not take into account varying operating theatre times. 38, 39 However, in our case, it is unlikely that a different costing approach would have shifted results in favour of the locking plate as the mean operating theatre times were the same (124 minutes) for both procedures and the cost of implants represented a relatively minor component of total costs.
In conclusion, our study provides a comprehensive assessment of the cost-effectiveness of two commonly undertaken treatments for distal tibia fractures with obvious implications for the orthopaedic community. Notwithstanding the limitations of within-trial analyses, this study provides robust evidence that over the first year after surgery, nail fixation is a cost-saving intervention without detriment to health-related quality of life outcomes. Given these results, there is economic justification for recommending nail rather than locking plate fixation for the management of extra-articular distal tibia fractures.
Take home message:
This paper adds important evidence on the cost-effectiveness of alternative treatment options for extra-articular fractures of the distal tibia.
Supplementary material
Tables showing: (i) health care resource use related to distal fracture fixation by each follow-up period and treatment arm for complete cases (individuals with complete cost and outcome data over the 12-month follow-up period) and (ii) Frequency and percentages of study population reporting levels 1 to 3 by EQ-5D dimension, treatment arm and follow-up period.
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